Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis

British Journal of Haematology

Volumn 117, Issue 4, 2002, Pages 886-889

  Sanchorawala, Vaishali ^a,b   Wright, Daniel G ^a   Seldin, David C ^a   Falk, Rodney H ^a   Berk, John L ^a   Dember, Laura M ^a   Finn, Kathleen T ^a   Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

AL amyloidosis; Melphalan

Indexed keywords

MELPHALAN; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; HEART AMYLOIDOSIS; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART DISEASES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0036283917     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03541.x     Document Type: Article

References (8)

1. Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma
2. Single-dose intravenous melphalan in advanced multiple myeloma
3. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
4. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone and colchicine
5. 2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment
6. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
7. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
8. Melphalan therapy in myelomatosis